• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Landos Biopharma to Present at the American College of Gastroenterology 2023 Annual Scientific Meeting

    10/23/23 8:00:00 AM ET
    $LABP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LABP alert in real time by email

    NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ:LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced that it will present additional findings from its Phase 1b study of NX-13 for the treatment of ulcerative colitis (UC), including detailed results on the rapid symptomatic relief and improvement in multiple clinical biomarkers observed in the study, at the American College of Gastroenterology (ACG) 2023 Annual Scientific Meeting, being held October 20-25 in Vancouver, Canada.

    "We are excited for the opportunity to present at a premier gastroenterology event like ACG and share additional findings from our Phase 1b study of NX-13 in patients with UC," said Gregory Oakes, President and CEO of Landos. "The presentations cover the rapid symptomatic relief and improvements in multiple biomarkers, correlating with early endoscopic response of NX-13 in patients with moderate-to-severe UC. The data highlight the potential of NX-13 to transform the standard of care in moderate-to-severe UC with an oral, once-daily treatment, and further our confidence in the ongoing NEXUS proof-of-concept trial."

    The Company continues to actively recruit, screen and randomize patients for the NEXUS trial, with topline results expected by the fourth quarter of 2024.

    Presentation Details

    Title: The Nucleotide-Binding Oligomerization Domain, Leucine Rich Repeat Containing X1 (NLRX1) Agonist NX-13 Demonstrates Rapid Symptomatic and Biomarkers Improvement in Ulcerative Colitis: Results In a Phase 1b Study (00997)

    Scientific Poster Session: P3607

    Date & Time: Tuesday, October 24, 2023 at 10:30am - 4:00pm PDT

    Title: Rapid Symptomatic Relief Is Correlated with Early Endoscopic Response to the Nucleotide-Binding Oligomerization Domain, Leucine Rich Repeat Containing X1 (NLRX1) Agonist NX-13 In Ulcerative Colitis: Results in a Phase 1b Study (00995)

    Scientific Poster Session: P3644

    Date & Time: Tuesday, October 24, 2023 at 10:30am - 4:00pm PDT

    Title: Target Engagement and Pharmacodynamic Molecular Mechanism Evaluation In A Phase 1b Study of The Nucleotide-Binding Oligomerization Domain, Leucine Rich Repeat Containing X1 (NLRX1) Agonist NX-13 in Ulcerative Colitis (00958)

    Scientific Poster Session: P3548

    Date & Time: Tuesday, October 24, 2023 at 10:30am - 4:00pm PDT

    About Landos Biopharma

    Landos Biopharma is a clinical stage biopharmaceutical company focused on the development of first-in-class, oral therapeutics for patients with autoimmune diseases. Our mission is to create safer and more effective treatments that address the therapeutic gap in the current treatment paradigm.

    We have a portfolio of novel targets anchoring two libraries of immunometabolic modulation pathways, including four potentially first-in-class, once-daily, oral therapies targeting eight indications in the immunology space.

    We are currently focused on advancing the clinical development of NX-13 in UC. We initiated the NEXUS Phase 2 proof-of-concept trial in the second quarter of 2023 and expect to report topline results by the fourth quarter of 2024.

    For more information, please visit www.landosbiopharma.com.

    Cautionary Note on Forward-Looking Statements

    Statements in this press release about future expectations, plans and prospects for Landos Biopharma, Inc. (the "Company"), including statements about the Company's strategy, clinical development and regulatory plans for its product candidates and other statements containing the words "anticipate", "plan", "expect", "may", "will", "could", "believe", "look forward", "potential", the negatives thereof, variations thereon and similar expressions, or any discussions of strategy constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties inherent in the initiation and enrollment of current and future clinical trials, including the ongoing Phase 2 trial of NX-13, availability and timing of data from ongoing clinical trials, expectations for regulatory approvals, other matters that could affect the availability or commercial potential of the Company's product candidates and other similar risks. Risks regarding the Company's business are described in detail in its Securities and Exchange Commission ("SEC") filings, including in its Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q, which are available on the SEC's website at www.sec.gov. Additional information will be made available in other filings that the Company makes from time to time with the SEC. In addition, the forward-looking statements included in this press release represent the Company's views only as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so, except as may be required by law. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.

    Contacts

    Rebecca Mosig, Vice President, Corporate Development

    Landos Biopharma

    [email protected]

    John Mullaly

    LifeSci Advisors, LLC

    [email protected]

     



    Primary Logo

    Get the next $LABP alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LABP

    DatePrice TargetRatingAnalyst
    4/12/2022$30.00 → $1.40Buy → Hold
    Jefferies
    1/3/2022$15.00 → $7.00Neutral
    JP Morgan
    11/16/2021$20.00 → $16.00Outperform → Market Perform
    SVB Leerink
    10/20/2021$45.00Buy
    Craig-Hallum
    10/19/2021$50.00Buy
    HC Wainwright & Co.
    9/23/2021$39.00Buy
    JonesTrading
    7/30/2021$33.00 → $35.00Outperform
    Raymond James
    More analyst ratings

    $LABP
    SEC Filings

    See more
    • SEC Form 15-12G filed by Landos Biopharma Inc.

      15-12G - Landos Biopharma, Inc. (0001785345) (Filer)

      6/3/24 6:04:57 AM ET
      $LABP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form RW filed by Landos Biopharma Inc.

      RW - Landos Biopharma, Inc. (0001785345) (Filer)

      5/23/24 4:52:59 PM ET
      $LABP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Landos Biopharma Inc.

      S-8 POS - Landos Biopharma, Inc. (0001785345) (Filer)

      5/23/24 4:49:28 PM ET
      $LABP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LABP
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • AbbVie Completes Acquisition of Landos Biopharma

      -   Adds first-in-class investigational asset, NX-13, to AbbVie's pipeline with the potential to offer a novel approach to the treatment of ulcerative colitis (UC) and Crohn's disease (CD) NORTH CHICAGO, Ill., May 23, 2024 /PRNewswire/ -- AbbVie (NYSE:ABBV) announced today that it has completed its acquisition of Landos Biopharma, Inc. (NASDAQ:LABP). With the completion of the acquisition, Landos is now part of AbbVie. Landos' lead investigational asset is NX-13, a first-in-class, oral NLRX1 agonist (a member of the NOD-like receptor family), which is currently in Phase 2 for the treatment of moderate to severe UC (NEXUS study; NCT05785715). NLRX1 regulates immunometabolism and inflammation,

      5/23/24 4:05:00 PM ET
      $ABBV
      $LABP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stockholder Alert: Ademi LLP continues Investigation of the Fairness of Landos Biopharma, Inc.'s transaction with AbbVie

      MILWAUKEE, April 16, 2024 /PRNewswire/ -- Ademi LLP investigation of Landos (NASDAQ:LABP) continues now that Landos has filed a preliminary proxy statement seeking stockholder approval for its transaction with AbbVie. Click here to learn how to join the https://www.ademilaw.com/case/landos-biopharma-inc or call Guri Ademi toll-free at 866-264-3995.  There is no cost or obligation to you. In the transaction, Landos shareholders will receive only $20.42 per share in cash upon closing, or approximately $137.5 million in the aggregate, plus one non-tradable contingent value right

      4/16/24 3:32:00 PM ET
      $LABP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune Diseases

      Landos' lead asset, NX-13, is a first-in-class, oral NLRX1 agonist in Phase 2 for the treatment of ulcerative colitis (UC)NORTH CHICAGO, Ill. and NEW YORK, March 25, 2024 /PRNewswire/ -- AbbVie Inc. (NYSE:ABBV) ("AbbVie") and Landos Biopharma, Inc. (NASDAQ:LABP) ("Landos") today announced a definitive agreement under which AbbVie will acquire Landos, a clinical stage biopharmaceutical company focused on the development of novel, oral therapeutics for patients with autoimmune diseases. Landos' lead investigational asset is NX-13, a first-in-class, oral NLRX1 agonist (a member of the NOD-like receptor family) with a bimodal mechanism of action (MOA), which is anti-inflammatory and facilitates

      3/25/24 8:31:00 AM ET
      $ABBV
      $LABP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LABP
    Financials

    Live finance-specific insights

    See more
    • Landos Biopharma Provides Comprehensive Update on Clinical Development Plans

      Advancing NX-13 Clinical Development for Treatment of Ulcerative Colitis On Track to Initiate Phase 2 Proof-of-Concept Trial for NX-13 in the Second Quarter of 2023 and Report Topline Data by the Fourth Quarter of 2024 Broader, Novel Pipeline Poised for Partnering and Continued Development in the Future; Significant Optionality for Omilancor, LABP-104 and Four Promising Pre-Clinical Programs Secures Additional $16.7 Million Investment Disciplined Financial Approach Expected to Maintain Cash Runway into First Half of 2025 Company to Host Investor Call at 8:00 AM ET NEW YORK, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ:LABP) ("Landos" or the "Company"), a clinical

      1/5/23 7:05:53 AM ET
      $LABP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Landos Biopharma Reports Third Quarter 2021 Financial Results and Provides Corporate Update

      Enhancing Focus on High-Impact Clinical-Stage Programs to Ensure Optimal Path to Commercialization Refining Ulcerative Colitis Clinical Development Plans for Omilancor to Generate Additional Phase 2b Data Prior to Initiating Pivotal Phase 3 Program Determining Optimal Enrollment for Phase 2 Clinical Study of Omilancor in Crohn's Disease and Phase 1b Study of NX-13 in UC Initiated Dosing for LABP-104 in Healthy Volunteers in October 2021 with Results Expected in 1H 2022 Corporate Update Conference Call Scheduled for 8:00 am ET Today BLACKSBURG, Va., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ:LABP), a clin

      11/15/21 7:30:00 AM ET
      $LABP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Landos Biopharma to Host Corporate Update Call

      BLACKSBURG, Va., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma Inc. (NASDAQ:LABP) today announced that it will report third quarter 2021 financial results and host a conference call to provide a corporate update on November 15, 2021. Following the release of the financial results, Landos will host a live webcast at 8:00 am ET. The webcast can be accessed through the Company's investor relations website at https://ir.landosbiopharma.com/, or by dialing 1-877-317-6789 (Toll Free) or 1-412-317-6789 (International) and asking to join the Landos Corporate Update call. The webcast will be archived and be available for replay on the Company's investor relations website. About Landos Biopha

      11/11/21 4:05:00 PM ET
      $LABP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LABP
    Leadership Updates

    Live Leadership Updates

    See more

    $LABP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $LABP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Stockholder Alert: Ademi LLP continues Investigation of the Fairness of Landos Biopharma, Inc.'s transaction with AbbVie

      MILWAUKEE, April 16, 2024 /PRNewswire/ -- Ademi LLP investigation of Landos (NASDAQ:LABP) continues now that Landos has filed a preliminary proxy statement seeking stockholder approval for its transaction with AbbVie. Click here to learn how to join the https://www.ademilaw.com/case/landos-biopharma-inc or call Guri Ademi toll-free at 866-264-3995.  There is no cost or obligation to you. In the transaction, Landos shareholders will receive only $20.42 per share in cash upon closing, or approximately $137.5 million in the aggregate, plus one non-tradable contingent value right

      4/16/24 3:32:00 PM ET
      $LABP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Landos Biopharma Provides Business Update & Reports Second Quarter 2023 Results

      Initiated NEXUS Phase 2 Clinical Trial of NX-13 for Ulcerative Colitis NEXUS Remains On Track With Top-line Results Planned for Q4 2024 Sufficient Cash to Fund Planned Operations into First Half of 2025 NEW YORK, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ:LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today provided a business update and announced financial results for the second quarter ended June 30, 2023. "We continued to advance and execute the NX-13 Phase 2 clinical program (NEXUS) during the second quarter. We have activated sites in the US and are actively recruiting and screening pa

      8/9/23 8:00:00 AM ET
      $LABP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Landos Biopharma Expands Board of Directors with Appointment of Alka Batycky, Ph.D.

      NEW YORK, May 30, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ:LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced the appointment of Alka Batycky, Ph.D. to its Board of Directors and Audit Committee. "Dr. Batycky is an accomplished biopharmaceutical executive and an important addition to Landos' Board," said Gregory Oakes, President and CEO of Landos. "Dr. Batycky has a proven track record, and we look forward to her contributions as we execute upon our focused strategy in immunology." Dr. Batycky brings with her over 25 years of global drug development experience in the biopharmaceutical in

      5/30/23 4:15:00 PM ET
      $LABP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Landos Biopharma downgraded by Jefferies with a new price target

      Jefferies downgraded Landos Biopharma from Buy to Hold and set a new price target of $1.40 from $30.00 previously

      4/12/22 7:27:34 AM ET
      $LABP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • JP Morgan reiterated coverage on Landos Biopharma with a new price target

      JP Morgan reiterated coverage of Landos Biopharma with a rating of Neutral and set a new price target of $7.00 from $15.00 previously

      1/3/22 11:17:54 AM ET
      $LABP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Landos Biopharma downgraded by SVB Leerink with a new price target

      SVB Leerink downgraded Landos Biopharma from Outperform to Market Perform and set a new price target of $16.00 from $20.00 previously

      11/16/21 7:18:20 AM ET
      $LABP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Landos Biopharma Inc. (Amendment)

      SC 13D/A - Landos Biopharma, Inc. (0001785345) (Subject)

      4/10/24 4:50:56 PM ET
      $LABP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Landos Biopharma Inc. (Amendment)

      SC 13D/A - Landos Biopharma, Inc. (0001785345) (Subject)

      4/10/24 4:50:26 PM ET
      $LABP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Landos Biopharma Inc. (Amendment)

      SC 13G/A - Landos Biopharma, Inc. (0001785345) (Subject)

      2/14/24 4:01:28 PM ET
      $LABP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LABP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Callori Fred

      4 - Landos Biopharma, Inc. (0001785345) (Issuer)

      5/23/24 5:45:25 PM ET
      $LABP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Mayleben Timothy M

      4 - Landos Biopharma, Inc. (0001785345) (Issuer)

      5/23/24 5:45:33 PM ET
      $LABP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Girao Tiago

      4 - Landos Biopharma, Inc. (0001785345) (Issuer)

      5/23/24 5:45:32 PM ET
      $LABP
      Biotechnology: Pharmaceutical Preparations
      Health Care